The information on this part of the website is intended only for health care professionals. I am an expert within the meaning of Act No. country xy. I herewith confirm that I am a professional according to this definition.
Unfortunately, as you are not a health care professional we cannot provide you this information.
Two trials with Limosilactobacillus reuteri Protectis (BioGaia) have shown it to have a positive effect on those suffering from FAP.
Of course, not all strains of probiotics are equal; different strains have different properties and effects. Limosilactobacillus reuteri Protectis is a powerful strain that colonizes the entire gastrointestinal (GI) tract.
Supports gastric emptying and improves GI motility
Can help to reduce the frequency and severity of pain
May improve gastric mucosal integrity
Promote overall digestive health in children and adults
Healthy bacterial balance in the digestive tract in balance contribute to gut comfort and overall wellbeing.
Limosilactobacillus reuteri Protectis has been shown to promote healthy digestive health and function.
One chewable tablet or 5 drops a day.
Limosilactobacillus reuteri Protectis (DSM 17938) vs placebo in children with functional abdominal pain.
Weizman Z., Blumin V. Abu-Abed J., Binsztok M.: J Pediatr. 2016:174:160-164.
Significant relief in frequency (p<0.02) and severity (p<0.01) of abdominal pain compared to placebo at 4 weeks.
Continuously and significantly relieved severity of abdominal pain compared to placebo at 8 weeks.
Reduced incidence of perceived abdominal distension and bloating compared to placebo at 4 weeks (p=0.013).
Demostrates that L. reuteri Protectis was effective in treating functional abdominal pain in children.
L. reuteri Protectis significantly reduced the frequency and severity of functional abdominal pain in children
Double blind, placebo-controlled study
93 children aged 6-15 years with functional abdominal pain (Rome III criteria)
One chewable tablet Limosilactobacillus reuteri Protectis (BioGaia) 108 CFU/day daily (n=47) or placebo (n=46) for 4 weeks with follow-up of additional 4 weeks
Limosilactobacillus reuteri Protectis (DSM 17938) in the treatment of functional abdominal pain in children.
Jadrešin O, Hojsak I, Mišak Z, Kekez AJ, Trbojević T, Ivković L, Kolaček S.
J Pediatr Gastroenterol Nutr. online 30 Nov 2016. doi: 10.1097/MPG.0000000000001478
Demonstrates that L. reuteri Protectis was effective in treating functional abdominal pain in childran
L. reuteri Protectis significantly reduced the number of days with pain and had a retained effect on severity of pain after supplementation of the study product had ended.